

## SUPPLEMENT INFORMATION

### **Autophagic Markers BECLIN-1 and LC3 are Associated with Prognosis of Multiple Myeloma**

Geunyoung Jung, Jin Roh, Hyangsin Lee, Minchan Gil, Dok Hyun Yoon, Cheolwon Suh, Seongsoo Jang, Chan-Jeoung Park, Jooryung Huh, and Chan-Sik Park

#### SUPPLEMENTARY FIGURE

Figure S1. Western blotting assays for BECLIN-1 and LC3.

The specificity of the antibodies is confirmed using western blotting analysis. Human breast cancer cell lines (HS578T) were left untreated (Control) and treated with anti-cancer drug BIX-01294 for 24h at 37°C in a 5% CO<sub>2</sub> humidified atmosphere (BIX-01294). BIX-01294, a selective inhibitor of euchromatic histone-lysine N-methyltransferase 2, is a strong autophagy inducer. Specific bands of LC3-I, LC3-II, and BECLIN-1 are detected by anti-LC3 antibody (Sigma, #L8918, 1:1,500) and anti-BECLIN-1 antibody (BD, #612112, 1:500) at 19 kDa, 17 kDa, and 52 kDa, respectively. The increase of BECLIN 1 and LC3-II are also specifically detected with corresponding antibodies after treatment of BIX-01294.

